Abstract:The Leucine-rich repeat kinase 2 (LRRK2) not only plays a vital role in familial forms of Parkinson's disease (PD) but is also considered as a risk factor for idiopathic PD. For these reasons, LRRK2 is considered a promising drug target for PD treatment. Its multi-domain architecture enables a fine-tuned regulation of its biological function by orchestrating intra- and inter-molecular interactions. At the same time, it offers multiple targetable epitopes for fine-tuned modulation of its deregulated kinase activity caused by pathogenic risk variants. Here, we present BioID proximity proteomes of LRRK2 revealing new interactors, which we further characterized by a novel evolutionary and structural bioinformatics pipeline. Co-evolutionary analysis of the protein-protein interaction (PPI) network identified a structural and functional module enriched in cytoskeletal components linked to the centrosome and microtubules. Likely co-evolved with LRRK2 within this cluster is CYLD, a K-63 selective ubiquitin deubiquitinase which we found to stabilize LRRK2. Furthermore, structural prediction of binary interactions via AlphaFold-multimer revealed distinct groups of interactors engaging with LRRK2 dependent on specific conformations and epitopes. We found two distinct groups engaging with LRRK2 either in an N-terminal closed ("locked") or open ("unlocked") conformation, both of which are associated with specific structurally defined interfaces and biological processes. Furthermore, we identified distinct changes in the LRRK2 proximity proteome induced by the type I kinase inhibitor MLi-2 or by co-expression of the LRRK2 upstream effector RAB29. Dependent on its state of activity and conformation, these functional state-specific protein interactions link LRRK2 to distinct cellular sub-compartments, including centriolar satellites as well as vesicular sub-compartments.

Proximity proteomics reveals a co-evolved LRRK2-regulatory network linked to centrosomes